However, randomized controlled trials evaluating ICI in NSCLC either have not included patients with ALK-rearrangements or have not had sufficient numbers of patients to provide meaningful subgroup analysis [31,32,33,34]. This evidence concerns the gene ALK and non-small cell lung carcinoma.